Active Not RecruitingNCT04884594
Safety of a gene-based treatment for cocaine use in remission
Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- RochesterSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 8, 2021
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 10
- Sponsor
- W. Michael Hooten
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04884594
- Official title
Show the full official title
Intravenous Administration of AAV8-human Cocaine Hydrolase to Treat Cocaine Use Disorder
Recruitment & locations
Not recruitingRochester
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is W. Michael Hooten.
Does this study involve medication?
Yes. The study involves medication, including AAV8-hCocH.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
